A pH-dilution method for estimation of biorelevant drug solubility along the gastrointestinal tract: Application to physiologically based pharmacokinetic modeling

Molecular Pharmaceutics

Volumn 7, Issue 5, 2010, Pages 1516-1526

  Gao, Yi ^a   Carr, Robert A ^a   Spence, Julie K ^a   Wang, Weili W ^a   Turner, Teresa M ^a   Lipari, John M ^a   Miller, Jonathan M ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

amorphous solid dispersions; biorelevant dissolution; GastroPlus; Physiologically based pharmacokinetic (PBPK) modeling; solubility enabling formulations

Indexed keywords

DIMETHYL SULFOXIDE; MACROGOL; NEW DRUG;

ANALYTIC METHOD; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; COMPUTER PROGRAM; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DILUTION; DISPERSION; DRUG FORMULATION; DRUG SOLUBILITY; GASTROINTESTINAL TRACT; MALE; NONHUMAN; PH; PRIORITY JOURNAL; RAT; SUSPENSION;

ADMINISTRATION, ORAL; ANIMALS; CHEMISTRY, PHARMACEUTICAL; HUMANS; HYDROGEN-ION CONCENTRATION; INTESTINAL ABSORPTION; MALE; MODELS, BIOLOGICAL; PHARMACOKINETICS; RATS; RATS, SPRAGUE-DAWLEY; SOLUBILITY; SUSPENSIONS;

EID: 77957735669     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp100157s     Document Type: Article

References (65)

1. Yu, L. X.; Amidon, G. L. A compartmental absorption and transit model for estimating oral drug absorption Int. J. Pharm. 1999, 186 (2) 119-25
2. Yu, L. X.; Gatlin, L.; Amidon, G. L. Predicting oral drug absorption in humans Drugs Pharm. Sci. 2000, 102 (Transport Processes in Pharmaceutical Systems) 377-409
3. Bolger, M. B.; Gilman, T. M.; Fraczkiewicz, R.; Steere, B.; Woltosz, W. S. Predicting drug absorption by computational methods Cell Cult. Models Biol. Barriers 2002, 353-377
4. Parrott, N.; Jones, H.; Paquereau, N.; Lave, T. Application of full physiological models for pharmaceutical drug candidate selection and extrapolation of pharmacokinetics to man Basic Clin. Pharmacol. Toxicol. 2005, 96 (3) 193-9
5. Parrott, N.; Paquereau, N.; Coassolo, P.; Lave, T. An evaluation of the utility of physiologically based models of pharmacokinetics in early drug discovery J. Pharm. Sci. 2005, 94 (10) 2327-43
6. Willmann, S.; Lippert, J.; Schmitt, W. From physicochemistry to absorption and distribution: predictive mechanistic modelling and computational tools Expert Opin. Drug Metab. Toxicol. 2005, 1 (1) 159-68
7. Dokoumetzidis, A.; Kalantzi, L.; Fotaki, N. Predictive models for oral drug absorption: from in silico methods to integrated dynamical models Expert Opin. Drug Metab. Toxicol. 2007, 3 (4) 491-505
8. Lave, T.; Parrott, N.; Grimm, H. P.; Fleury, A.; Reddy, M. Challenges and opportunities with modelling and simulation in drug discovery and drug development Xenobiotica 2007, 37 (10-11) 1295-310
9. Dong, J. Q.; Chen, B.; Gibbs, M. A.; Emery, M.; Gibbs, J. P. Applications of computer-aided pharmacokinetic and pharmacodynamic methods from drug discovery through registration Curr. Comput.-Aided Drug Des. 2008, 4 (1) 54-66
10. Parrott, N.; Lave, T. Applications of physiologically based absorption models in drug discovery and development Mol. Pharmaceutics 2008, 5 (5) 760-75
11. Bolger, M. B.; Fraczkiewicz, R.; Lukacova, V. Simulations of absorption, metabolism, and bioavailability Methods Princ. Med. Chem. 2009, 40 (Drug Bioavailability) 453-495
12. Huang, W.; Lee, S. L.; Yu, L. X. Mechanistic approaches to predicting oral drug absorption AAPS J. 2009, 11 (2) 217-24
13. Parrott, N.; Lave, T. Prediction of intestinal absorption: comparative assessment of GASTROPLUS and IDEA Eur. J. Pharm. Sci. 2002, 17 (1-2) 51-61
14. Stoner, C. L.; Cleton, A.; Johnson, K.; Oh, D. M.; Hallak, H.; Brodfuehrer, J.; Surendran, N.; Han, H. K. Integrated oral bioavailability projection using in vitro screening data as a selection tool in drug discovery Int. J. Pharm. 2004, 269 (1) 241-9
15. Bolger, M. B.; Fraczkiewicz, R.; Steere, B. In silico surrogates for in vivo properties: Profiling for ADME and toxicological behavior Exploit. Chem. Diversity Drug Discovery 2006, 364-385
16. Kuentz, M.; Nick, S.; Parrott, N.; Rothlisberger, D. A strategy for preclinical formulation development using GastroPlus as pharmacokinetic simulation tool and a statistical screening design applied to a dog study Eur. J. Pharm. Sci. 2006, 27 (1) 91-9
17. Tubic, M.; Wagner, D.; Spahn-Langguth, H.; Bolger, M. B.; Langguth, P. In silico modeling of non-linear drug absorption for the P-gp substrate talinolol and of consequences for the resulting pharmacodynamic effect Pharm. Res. 2006, 23 (8) 1712-20
18. De Buck, S. S.; Sinha, V. K.; Fenu, L. A.; Gilissen, R. A.; Mackie, C. E.; Nijsen, M. J. The prediction of drug metabolism, tissue distribution, and bioavailability of 50 structurally diverse compounds in rat using mechanism-based absorption, distribution, and metabolism prediction tools Drug Metab. Dispos. 2007, 35 (4) 649-59
19. De Buck, S. S.; Sinha, V. K.; Fenu, L. A.; Nijsen, M. J.; Mackie, C. E.; Gilissen, R. A. Prediction of human pharmacokinetics using physiologically based modeling: a retrospective analysis of 26 clinically tested drugs Drug Metab. Dispos. 2007, 35 (10) 1766-80
20. Kovacevic, I.; Parojcic, J.; Homsek, I.; Tubic-Grozdanis, M.; Langguth, P. Justification of Biowaiver for Carbamazepine, a Low Soluble High Permeable Compound, in Solid Dosage Forms Based on IVIVC and Gastrointestinal Simulation Mol. Pharmaceutics 2009, 6, 40-7
21. Kuentz, M. Drug absorption modeling as a tool to define the strategy in clinical formulation development AAPS J. 2008, 10 (3) 473-9
22. Seng, K. Y.; Nestorov, I.; Vicini, P. Physiologically based pharmacokinetic modeling of drug disposition in rat and human: a fuzzy arithmetic approach Pharm. Res. 2008, 25 (8) 1771-81
23. Tubic-Grozdanis, M.; Bolger, M. B.; Langguth, P. Application of gastrointestinal simulation for extensions for biowaivers of highly permeable compounds AAPS J. 2008, 10 (1) 213-26
24. Heimbach, T.; Lakshminarayana, S. B.; Hu, W.; He, H. Practical anticipation of human efficacious doses and pharmacokinetics using in vitro and preclinical in vivo data AAPS J. 2009, 11 (3) 602-14
25. Bolger, M. B.; Lukacova, V.; Woltosz, W. S. Simulations of the nonlinear dose dependence for substrates of influx and efflux transporters in the human intestine AAPS J. 2009, 11 (2) 353-63
26. Fenneteau, F.; Li, J.; Nekka, F. Assessing drug distribution in tissues expressing P-glycoprotein using physiologically based pharmacokinetic modeling: identification of important model parameters through global sensitivity analysis J. Pharmacokinet. Pharmacodyn. 2009, 36 (6) 495-522
27. Okumu, A.; DiMaso, M.; Lobenberg, R. Computer simulations using GastroPlus to justify a biowaiver for etoricoxib solid oral drug products Eur. J. Pharm. Biopharm. 2009, 72 (1) 91-8
28. Parrott, N.; Lukacova, V.; Fraczkiewicz, G.; Bolger, M. B. Predicting pharmacokinetics of drugs using physiologically based modeling - application to food effects AAPS J. 2009, 11 (1) 45-53
29. Watanabe, T.; Kusuhara, H.; Maeda, K.; Shitara, Y.; Sugiyama, Y. Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans J. Pharmacol. Exp. Ther. 2009, 328 (2) 652-62
30. Nicolaides, E.; Galia, E.; Efthymiopoulos, C.; Dressman, J. B.; Reppas, C. Forecasting the in vivo performance of four low solubility drugs from their in vitro dissolution data Pharm. Res. 1999, 16 (12) 1876-82
31. Yu, L. X. An integrated model for determining causes of poor oral drug absorption Pharm. Res. 1999, 16 (12) 1883-7
32. Hendriksen Barry, A.; Felix Manuel, V. S.; Bolger Michael, B. The composite solubility versus pH profile and its role in intestinal absorption prediction AAPS PharmSci 2003, 5 (1 E4
33. Jones, H. M.; Parrott, N.; Ohlenbusch, G.; Lave, T. Predicting pharmacokinetic food effects using biorelevant solubility media and physiologically based modelling Clin. Pharmacokinet. 2006, 45 (12) 1213-26
34. Wei, H.; Lobenberg, R. Biorelevant dissolution media as a predictive tool for glyburide a class II drug Eur. J. Pharm. Sci. 2006, 29 (1) 45-52
35. Li, P.; Zhao, L. Developing early formulations: practice and perspective Int. J. Pharm. 2007, 341 (1-2) 1-19
36. Aburub, A.; Risley, D. S.; Mishra, D. A critical evaluation of fasted state simulating gastric fluid (FaSSGF) that contains sodium lauryl sulfate and proposal of a modified recipe Int. J. Pharm. 2008, 347 (1-2) 16-22
37. Kesisoglou, F.; Wu, Y. Understanding the effect of API properties on bioavailability through absorption modeling AAPS J. 2008, 10 (4) 516-25
38. Okumu, A.; DiMaso, M.; Lobenberg, R. Dynamic dissolution testing to establish in vitro/in vivo correlations for montelukast sodium, a poorly soluble drug Pharm. Res. 2008, 25 (12) 2778-85
39. Wei, H.; Dalton, C.; Di Maso, M.; Kanfer, I.; Lobenberg, R. Physicochemical characterization of five glyburide powders: a BCS based approach to predict oral absorption Eur. J. Pharm. Biopharm. 2008, 69 (3) 1046-56
40. Lukacova, V.; Woltosz, W. S.; Bolger, M. B. Prediction of modified release pharmacokinetics and pharmacodynamics from in vitro, immediate release, and intravenous data AAPS J. 2009, 11 (2) 323-34
41. Shono, Y.; Jantratid, E.; Janssen, N.; Kesisoglou, F.; Mao, Y.; Vertzoni, M.; Reppas, C.; Dressman, J. B. Prediction of food effects on the absorption of celecoxib based on biorelevant dissolution testing coupled with physiologically based pharmacokinetic modeling Eur. J. Pharm. Biopharm. 2009, 73 (1) 107-14
42. Li, P.; Zhao, L. Developing early formulations: practice and perspective Int. J. Pharm. 2007, 341 (1-2) 1-19
43. Sanghvi, R.; Mogalian, E.; Machatha, S. G.; Narazaki, R.; Karlage, K. L.; Jain, P.; Tabibi, S. E.; Glaze, E.; Myrdal, P. B.; Yalkowsky, S. H. Preformulation and pharmacokinetic studies on antalarmin: a novel stress inhibitor J. Pharm. Sci. 2009, 98 (1) 205-14
44. Schamp, K.; Schreder, S. A.; Dressman, J. Development of an in vitro/in vivo correlation for lipid formulations of EMD 50733, a poorly soluble, lipophilic drug substance Eur. J. Pharm. Biopharm. 2006, 62 (3) 227-34
45. Dahan, A.; Hoffman, A. Rationalizing the selection of oral lipid based drug delivery systems by an in vitro dynamic lipolysis model for improved oral bioavailability of poorly water soluble drugs J. Controlled Release 2008, 129 (1) 1-10
46. Fatouros, D. G.; Mullertz, A. Using in vitro dynamic lipolysis modeling as a tool for exploring IVIVC relationships for oral lipid-based formulations Drugs Pharm. Sci. 2007, 170 (Oral Lipid-Based Formulations) 257-271
47. Fatouros, D. G.; Nielsen, F. S.; Douroumis, D.; Hadjileontiadis, L. J.; Mullertz, A. In vitro-in vivo correlations of self-emulsifying drug delivery systems combining the dynamic lipolysis model and neuro-fuzzy networks Eur. J. Pharm. Biopharm. 2008, 69 (3) 887-98
48. Kostewicz, E. S.; Wunderlich, M.; Brauns, U.; Becker, R.; Bock, T.; Dressman, J. B. Predicting the precipitation of poorly soluble weak bases upon entry in the small intestine J. Pharm. Pharmacol. 2004, 56 (1) 43-51
49. Murphy, D.; Rodriguez-Cintron, F.; Langevin, B.; Kelly, R. C.; Rodriguez-Hornedo, N. Solution-mediated phase transformation of anhydrous to dihydrate carbamazepine and the effect of lattice disorder Int. J. Pharm. 2002, 246 (1-2) 121-34
50. Gao, P.; Morozowich, W. Development of supersaturatable self-emulsifying drug delivery system formulations for improving the oral absorption of poorly soluble drugs Expert Opin. Drug Delivery 2006, 3 (1) 97-110
51. Carino, S. R.; Sperry, D. C.; Hawley, M. Relative bioavailability estimation of carbamazepine crystal forms using an artificial stomach-duodenum model J. Pharm. Sci. 2006, 95 (1) 116-25
52. Gu, C. H.; Rao, D.; Gandhi, R. B.; Hilden, J.; Raghavan, K. Using a novel multicompartment dissolution system to predict the effect of gastric pH on the oral absorption of weak bases with poor intrinsic solubility J. Pharm. Sci. 2005, 94 (1) 199-208
53. Stahlin, F. O.; Schmid, G.; Hempel, K.; Heidland, A. Technique of continuous collection of parotid saliva in the rat Res. Exp. Med. (Berlin) 1978, 172 (3) 247-53
54. http://www.rivm.nl/interspeciesinfo/intra/rat/stomach/db-rat-stomach.jsp.
55. From GastroPlus program, gastric residence time of fasted rats.
56. Shaw, H. M.; Heath, T. J. Basal and postprandial pancreatic secretion in rats Q. J. Exp. Physiol. Cogn. Med. Sci. 1973, 58 (4) 335-43
57. Kararli, T. T. Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals Biopharm. Drug Dispos. 1995, 16 (5) 351-80
58. From GastroPlus program, intestine residence time of fasted rats
59. Sutton, S. C. Role of physiological intestinal water in oral absorption AAPS J. 2009, 11 (2) 277-85
60. Reppas, C.; Dressman, J. Physiologically based dissolution tests for immediate release dosage forms: In vitro conditions and data analysis Bull. Tech. Gattefosse 1998, 91, 47-54
61. Rodgers, T.; Leahy, D.; Rowland, M. Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases J. Pharm. Sci. 2005, 94 (6) 1259-76
62. Rodgers, T.; Rowland, M. Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions J. Pharm. Sci. 2006, 95 (6) 1238-57
63. Amidon, G. E.; Higuchi, W. I.; Ho, N. F. Theoretical and experimental studies of transport of micelle-solubilized solutes J. Pharm. Sci. 1982, 71 (1) 77-84
64. Ho, N. F. H.; Park, J. Y.; Ni, P. F.; Higuchi, W. I. Advancing quantitative and mechanistic approaches in interfacing gastrointestinal drug absorption studies in animals and humans Anim. Models Oral Drug Delivery Man: In Situ In Vivo Approaches, Symp. 1983, 27-106
65. Dahan, A.; Miller, J. M.; Hoffman, A.; Amidon, G. E.; Amidon, G. L. The solubility-permeability interplay in using cyclodextrins as pharmaceutical solubilizers: mechanistic modeling and application to progesterone J. Pharm. Sci. 2010, 99 (6) 2739-49